- Home
- PCM vs ANVS Comparison
PCM vs ANVS Comparison
Compare PCM & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCM | ANVS |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 76.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PCM | ANVS |
|---|---|---|
| Price | $5.29 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 58.7K | ★ 529.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.22 | $1.54 |
| 52 Week High | $6.76 | $5.50 |
Technical Indicators
Market Signals| Indicator | PCM | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 30.03 | 30.28 |
| Support Level | $5.29 | N/A |
| Resistance Level | $5.83 | $2.02 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 22.67 | 10.18 |
Price Performance
Historical ComparisonAbout PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.